Regeneron Pharmaceuticals Inc (NASDAQ:REGN)

555.23
Delayed Data
As of Sep 18
 -9.77 / -1.73%
Today’s Change
271.37
Today|||52-Week Range
664.64
+47.87%
Year-to-Date
Sorrento Gets FDA Nod for Phase I Study on Coronavirus Antibody
Sep 18 / Zacks.com - Paid Partner Content
Sanofi's Dupixent Gets Breakthrough Status for New Indication
Sep 14 / Zacks.com - Paid Partner Content
Pharma Stock Roundup: AZN, LLY & PFE's Coronavirus Updates, MRK's New Cancer Deals
Sep 18 / Zacks.com - Paid Partner Content
Regeneron's anti-viral antibody cocktail to be evaluated in Oxford's Phase 3 RECOVERY trial
Sep 14 / Seeking Alpha - Paid Partner Content
Roche's Actemra Meets Goal in Phase III Coronavirus Study
Sep 18 / Zacks.com - Paid Partner Content
Sanofi's Dupixent Fast Track'd for eosinophilic esophagitis
Sep 14 / Seeking Alpha - Paid Partner Content
Sanofi/Regeneron Libtayo shows positive effect in skin cancer study
Sep 18 / Seeking Alpha - Paid Partner Content
Sanofi's Dupixent nabs accelerated review in U.S. for eosinophilic esophagitis
Sep 14 / Seeking Alpha - Paid Partner Content
Tracking William Nygren's Harris Associates Portfolio - Q2 2020 Update
Sep 17 / Seeking Alpha - Paid Partner Content
2 Biotech Stocks with Jaw-Dropping Growth Potential
Sep 13 / MotleyFool.com - Paid Partner Content
Why Sorrento Therapeutics Stock Is Ripping Higher Today
Sep 17 / MotleyFool.com - Paid Partner Content
Blueprint Receives FDA Approval, And Other News: The Good, Bad And Ugly Of Biopharma
Sep 10 / Seeking Alpha - Paid Partner Content
Monoclonal Antibody Data
Sep 17 / Seeking Alpha - Paid Partner Content
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Citi's 15th Annual BioPharma Virtual Conference (Transcript)
Sep 09 / Seeking Alpha - Paid Partner Content
Biotech Stock Roundup: GILD to Buy IMMU, SGEN Collaborates With Merck & More
Sep 16 / Zacks.com - Paid Partner Content
2 Coronavirus Treatment Stocks to Buy Right Now
Sep 09 / MotleyFool.com - Paid Partner Content
2 COVID-19 Antibody Stocks to Buy Right Now
Sep 16 / MotleyFool.com - Paid Partner Content
Here's Why AstraZeneca (AZN) Stock is Up This Year So Far
Sep 08 / Zacks.com - Paid Partner Content
Scientists isolate tiny antibody that neutralizes SARS-CoV-2
Sep 15 / Seeking Alpha - Paid Partner Content
Sanofi/Regeneron Dupixent shows sustained benefit in asthma extension study
Sep 08 / Seeking Alpha - Paid Partner Content
Regeneron Pharmaceuticals, Inc. (REGN) Management at Cantor Fitzgerald Virtual Global Healthcare Conference Transcript
Sep 15 / Seeking Alpha - Paid Partner Content
Graybug Vision readies IPO
Sep 05 / Seeking Alpha - Paid Partner Content
Lilly's Olumiant Meets Primary Endpoint in Coronavirus Study
Sep 15 / Zacks.com - Paid Partner Content
Sanofi's late-stage Kevzara trial in COVID-19 patients fails to meet endpoints
Sep 01 / Seeking Alpha - Paid Partner Content
Regeneron's Cocktail for Coronavirus Selected for RECOVERY Study
Sep 15 / Zacks.com - Paid Partner Content
COVID-19 Treatments: Remdesivir Disappoints, Antiviral SPL7013 And Monoclonal Antibodies Interesting For Prevention/Early-Stage Treatment
Aug 27 / Seeking Alpha - Paid Partner Content
Could This COVID-19 Drug Developer's Stock Make You Filthy Rich?
Sep 15 / MotleyFool.com - Paid Partner Content
Baird notes hot competition marks heavy headwinds for a COVID-19 treatment maker
Aug 26 / Seeking Alpha - Paid Partner Content
Why Ziopharm Oncology Shares Zoomed Higher Today
Sep 14 / MotleyFool.com - Paid Partner Content
Outlook Therapeutics: Interpreting The New Phase 3 Trial Results
Aug 26 / Seeking Alpha - Paid Partner Content
Regeneron Pharmaceuticals, Inc. (REGN) Management Presents at Morgan Stanley 18th Annual Global Healthcare Conference (Transcript)
Sep 14 / Seeking Alpha - Paid Partner Content
COVID-19 vaccine-stoked buying pressures antibody developers
Aug 24 / Seeking Alpha - Paid Partner Content
Is Regeneron Pharmaceuticals (REGN) Outperforming Other Medical Stocks This Year?
Sep 14 / Zacks.com - Paid Partner Content
Investors in COVID-19 stocks face turmoil in coming weeks on vaccine data readouts
Aug 22 / Seeking Alpha - Paid Partner Content
Novartis Reports Positive Data on Beovu for DME Indication
Sep 14 / Zacks.com - Paid Partner Content